Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 15, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 in New York City. Mike Mahoney, chairman and chief...
-
May 10, 2019New data further support use of S-ICD System as first-line therapy for majority of ICD patients
Boston Scientific (NYSE: BSX) today announced acute results from the UNTOUCHED study evaluating safety and efficacy of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System for...
-
May 9, 2019Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the...
-
May 7, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City. Art Butcher, senior vice president and president,...
-
May 6, 2019New Stent System Now Available for Treating Patients with Deep Venous Blockages
Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive...
-
May 1, 2019
Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San...
-
May 1, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in the Bank of America Merrill Lynch Healthcare Conference 2019 on Wednesday, May 15, 2019 in Las Vegas. Dan Brennan, executive vice...
-
Apr 24, 2019
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an...
-
Apr 23, 2019Transcatheter Aortic Valve Replacement Technology for Patients with Severe Aortic Stenosis Designed to Minimize Paravalvular Leakage, Offer Controlled Delivery and Repositionability Post Deployment
Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic Valve System. Delivered via a...
-
Apr 16, 2019
On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse (POP) to stop selling and...
-
Mar 27, 2019
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24,...
-
Mar 17, 2019New data showcasing performance of recently acquired RF balloon-based, single-shot ablation technology
Boston Scientific Corporation (NYSE: BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA 2019, the annual congress of the European Heart...
-
Mar 13, 2019Company begins limited market release in Europe
Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in
-
Mar 11, 2019
Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on...
-
Feb 28, 2019
Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions MARLBOROUGH, Mass., February 28,...
-
Feb 27, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston. Dan Brennan, executive vice president...
-
Feb 25, 2019
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes...
-
Feb 21, 2019
Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under the Company's shelf registration...
-
Feb 14, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 in New York City. Joe Fitzgerald, executive...
-
Feb 12, 2019
On February 12, 2019, the U.S. Food and Drug Administration (FDA) convened an advisory panel of experts to discuss the safety and effectiveness of surgical mesh placed transvaginally to treat...
-
Feb 6, 2019
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent on a reported basis, 8.2 percent on an...
-
Jan 25, 2019
Boston Scientific Corporation (NYSE: BSX) today announced that data from a randomized clinical trial demonstrate that Rezūm™ Water Vapor Therapy, a minimally invasive treatment for benign...
-
Jan 24, 2019Advanced systems offer customizable therapy addressing progression of Parkinson's disease
Boston Scientific Corporation (NYSE: BSX) has launched the Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia™ Directional...
-
Jan 22, 2019Results from the VIRTUS Study Show Venous Stent Met Its Primary Effectiveness and Safety Endpoints in Re-establishing Blood Flow at Twelve Months
Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions...
-
Jan 15, 2019All Patent Litigation Between the Companies to be Dismissed
Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation (NYSE: EW) today announced that the companies have reached an agreement to settle all outstanding patent disputes...